Lesion Size Measurement During Gastrointestinal Endoscopies
Recruiting now NCT07770425
Run by Centre hospitalier de l'Université de Montréal (CHUM) · for 18 and older · All sexes
What this study is about
The goal of this prospective observational study is to assess the accuracy and reliability of laser readings obtained through AccuMeasure, in comparison to other measurements performed by gastroenterologists. AccuMeasure is a novel technology, that has emerged as a promising tool for measuring polyps and lesions during colonoscopies. The system employs laser-based measurements, enabling precise determination of lesion size, depth, and extent. The main hypotheses this study aims to evaluate are: * AccuMeasure technology, with its precise laser measurements, will demonstrate superior accuracy and reliability in assessing lesion size of pathologies encountered during endoscopies, when compared to other endoscopic scoring methods. * AccuMeasure measurements will show strong construct validity by correlating significantly with endoscopic subscores, symptomatic remission (CD PRO2 \<8, partial mayo score), and fecal calprotectin values.
Who can join (things the study team will check)
✅ You may be able to join if…
- Adult patients (18 years and older)
- Patients undergoing gastrointestinal endoscopy procedures
🚫 You may not be able to join if…
- Minors: Patients under 18 years of age.
- Patients who do not provide informed consent.
- Patients undergoing endoscopy on an emergency basis (defined as urgent diagnostic or therapeutic endoscopy performed on the gastrointestinal (GI) tract to address potentially life-threatening conditions or severe symptoms that require immediate medical attention).
- An American Society of Anesthesiologists (ASA) physical status classification greater than 3.
Where this trial is running
- Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
Verify everything on the official ClinicalTrials.gov record. Page updated September 2026.